week 3 semaglutide no weight loss Today is our injection of a compounded semaglutide. I am so far not feeling any different, I have lost zero weight, I still have cravings, but we are trusting the process. I don't think I got Compounded semaglutide not working?

Dietary fibre plays a crucial role in promoting regular bowel movements

As a patient, your compounded semaglutide or tirzepatide: Requires a prescription Is prepared based on your providers instructions Comes from a licensed facility with documented safety protocols Your safety is our top priorityand our partnerships reflect that

Mechanisms of Action Retatrutide activates three key receptors to modulate energy balance, appetite, and metabolism, leading to profound weight loss and glycemic control.[1][2] This triple agonism differentiates it from dual agonists like tirzepatide, enhancing fat oxidation and insulin sensitivity.[3][10] Key sub-mechanisms include: GLP-1 Receptor Activation : Suppresses appetite, delays gastric emptying, and promotes insulin secretion in a glucose-dependent manner.[1][11] GIP Receptor Activation : Enhances insulinotropic effects and improves beta-cell function, contributing to postprandial glucose control.[2][12] Glucagon Receptor Activation : Increases energy expenditure, promotes lipolysis, and supports hepatic fat reduction without significant hyperglycemia.[1][13] Synergistic Metabolic Regulation : Combines receptor effects to amplify weight loss through reduced caloric intake and increased thermogenesis.[3][14] Cardiometabolic Protection : Improves lipid profiles and reduces inflammation via multi-pathway modulation.[4][15] These mechanisms highlight Retatrutide's potential for compounding in therapies targeting obesity and related comorbidities

most patients experience these mildly or not at all by the time they reach this dose level

A patient with a BMI of 35 aiming for a BMI under 25 follows a different timeline than someone with a BMI of 28, and genetic testing can predict which patients typically respond faster

Bonora et al., 2021)